Cannabis Has Opposite Effects on Brain Signal Processing in Schizophrenia Patients Versus Healthy People

Chronic cannabis use impaired a measure of brain signal filtering (P200 suppression) in healthy people but paradoxically improved it in schizophrenia patients, suggesting the endocannabinoid system functions differently in schizophrenia.

Rentzsch, Johannes et al.·Biological psychiatry. Cognitive neuroscience and neuroimaging·2017·Moderate EvidenceCase-Control
RTHC-01499Case ControlModerate Evidence2017RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Case-Control
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

Researchers measured how the brain filters repeated auditory signals in four groups: schizophrenia patients with and without cannabis use, and healthy controls with and without cannabis use. They focused on "repetition suppression," where the brain normally dampens its response to a repeated sound.

For the P200 brain wave component, cannabis had opposite effects depending on diagnosis. In healthy controls, chronic cannabis use was associated with worse suppression (0.55 vs. 0.40, p < 0.02), meaning poorer signal filtering. In schizophrenia patients, cannabis use was associated with better suppression (0.36 vs. 0.54, p < 0.02), meaning improved signal filtering.

Among healthy controls, total lifetime cannabis consumption correlated with worse P200 suppression (r = 0.28, p < 0.007). Among schizophrenia patients, longer time since last cannabis use correlated with worse P200 suppression (r = 0.42, p < 0.002), suggesting the benefit faded with abstinence.

Key Numbers

34 schizophrenia patients with cannabis, 33 without. 45 controls with cannabis, 61 without. Interaction between diagnosis and cannabis on P200 suppression: p < 0.001. Cannabis-using controls: suppression ratio 0.55. Non-using controls: 0.40. Cannabis-using schizophrenia: 0.36. Non-using schizophrenia: 0.54.

How They Did This

Mixed-sample study with 34 schizophrenia patients and 45 healthy controls who were chronic heavy cannabis users, plus 33 schizophrenia patients and 61 healthy controls without cannabis use. Auditory event-related potentials were recorded using a paired-stimulus paradigm measuring P50, N100, and P200 repetition suppression.

Why This Research Matters

This study provides neurophysiological evidence for the paradox of cannabis use in schizophrenia: while cannabis is a risk factor for psychosis, many patients report subjective benefits. The opposing effects on P200 suppression suggest that the endocannabinoid system may be fundamentally altered in schizophrenia, meaning cannabis interacts with a different neurological landscape in these patients.

The Bigger Picture

The relationship between cannabis and schizophrenia is not simply "cannabis causes psychosis." This study reveals that the neurobiological effects of cannabis differ fundamentally between healthy brains and brains affected by schizophrenia. This divergence likely reflects underlying alterations in the endocannabinoid system that are part of schizophrenia itself, not just a consequence of cannabis use.

What This Study Doesn't Tell Us

Cross-sectional design cannot determine causation. Cannabis users in both groups may differ from non-users in ways beyond cannabis exposure (other substance use, medication differences). P200 suppression is one of many possible measures of sensory processing, and its clinical relevance is debated. The study measured chronic heavy use and did not assess the effects of different doses or patterns of use.

Questions This Raises

  • ?Could endocannabinoid system abnormalities in schizophrenia be a target for treatment?
  • ?Does the paradoxical improvement in P200 suppression with cannabis in schizophrenia translate to any functional benefit?
  • ?Would targeted cannabinoid therapies improve sensory processing in schizophrenia without the risks of cannabis use?

Trust & Context

Key Stat:
Cannabis improved P200 suppression in schizophrenia (p < 0.02) but impaired it in healthy controls (p < 0.02)
Evidence Grade:
Moderate evidence from a well-designed case-control study with adequate sample sizes, though limited by cross-sectional design.
Study Age:
Published in 2017. Contributes to understanding of endocannabinoid system alterations in schizophrenia.
Original Title:
Opposing Effects of Cannabis Use on Late Auditory Repetition Suppression in Schizophrenia Patients and Healthy Control Subjects.
Published In:
Biological psychiatry. Cognitive neuroscience and neuroimaging, 2(3), 263-271 (2017)
Database ID:
RTHC-01499

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-ControlFollows or compares groups over time
This study
Cross-Sectional / Observational
Case Report / Animal Study

Compares people with a condition to similar people without it.

What do these levels mean? →

Frequently Asked Questions

Does this mean cannabis helps schizophrenia?

Not exactly. The study found that cannabis improved one specific measure of brain signal processing in schizophrenia patients. However, cannabis use remains associated with overall worse outcomes in schizophrenia, including more frequent psychotic episodes and hospitalizations. One positive neurophysiological finding does not outweigh the established risks.

Why would cannabis have opposite effects in healthy versus schizophrenia brains?

The researchers suggest this reflects underlying alterations in the endocannabinoid system that are part of schizophrenia. In a healthy brain, cannabis disrupts normal endocannabinoid signaling. In schizophrenia, where the system is already altered, cannabis may partially compensate for existing deficits in certain neural circuits.

Read More on RethinkTHC

Cite This Study

RTHC-01499·https://rethinkthc.com/research/RTHC-01499

APA

Rentzsch, Johannes; Kronenberg, Golo; Stadtmann, Ada; Neuhaus, Andres; Montag, Christiane; Hellweg, Rainer; Jockers-Scherübl, Maria Christiane. (2017). Opposing Effects of Cannabis Use on Late Auditory Repetition Suppression in Schizophrenia Patients and Healthy Control Subjects.. Biological psychiatry. Cognitive neuroscience and neuroimaging, 2(3), 263-271. https://doi.org/10.1016/j.bpsc.2016.10.004

MLA

Rentzsch, Johannes, et al. "Opposing Effects of Cannabis Use on Late Auditory Repetition Suppression in Schizophrenia Patients and Healthy Control Subjects.." Biological psychiatry. Cognitive neuroscience and neuroimaging, 2017. https://doi.org/10.1016/j.bpsc.2016.10.004

RethinkTHC

RethinkTHC Research Database. "Opposing Effects of Cannabis Use on Late Auditory Repetition..." RTHC-01499. Retrieved from https://rethinkthc.com/research/rentzsch-2017-opposing-effects-of-cannabis

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.